Modified Number of Extranodal Involved Sites as a Prognosticator in R-CHOP-Treated Patients with Disseminated Diffuse Large B-Cell Lymphoma
Changhoon Yoo, Shin Kim, Byeong Seok Sohn, Jeong-Eun Kim, Dok Hyun Yoon, Jooryung Huh, Dae Ho Lee, Sang-We Kim, Jung-Shin Lee, Cheolwon Suh
Korean J Intern Med. 2010;25(3):301-308. Published online 2010 Aug 31 DOI: https://doi.org/10.3904/kjim.2010.25.3.301
Citations to this article as recorded by 
Primary extranodal diffuse large B‐cell lymphoma: Molecular features, treatment, and prognosis
Si‐Yuan Chen, Meng‐Meng Ji, Peng‐Peng Xu, Wei‐Li Zhao
Aging and Cancer.2022; 3(3-4): 133. CrossRef
Clinical Impact of Extranodal Metabolic Tumor Volume in 240 Diffuse Large B cell Lymphoma Patients with Extranodal Involvement
Moo-Kon Song, Joo-Seop Chung, Sung-Nam Lim, Won-Sik Lee, Sang-Min Lee, Seong-Jang Kim, Hye-Kyung Shim, Seok-Mo Lee
Annals of Hematology.2021; 100(5): 1221. CrossRef
Role of Cell-Origin Profiling Using Immunohistochemistry to Predict the Survival of Patients with Diffuse Large B-Cell Lymphoma in Indonesia
Hermawan Istiadi, Udadi Sadhana, Dik Puspasari, Ika Pawitra Miranti, Vega Karlowee, Devia Eka Listiana, Awal Prasetyo
Yonago Acta Medica.2021; 64(2): 200. CrossRef
Pattern of extranodal involvement and its impact on survival in diffuse large B-cell lymphoma from a tertiary cancer center in rural India
Chandran K. Nair, Anju R. Kurup, A. Manuprasad, Praveen Kumar Shenoy, Vineetha Raghavan
Journal of Cancer Research and Therapeutics.2021; 17(4): 938. CrossRef
YAYGIN BÜYÜK B HÜCRELİ LENFOMA (YBBHL) TANILI OLGULARIN RETROSPEKTİF DEĞERLENDİRMESİ
Atakan TEKİNALP, Sinan DEMİRCİOĞLU, Volkan KARAKUŞ, Özcan ÇENELİ, Burhan TURGUT
Namık Kemal Tıp Dergisi.2020;[Epub] CrossRef
Lymphoma epidemiology in Korea and the real clinical field including the Consortium for Improving Survival of Lymphoma (CISL) trial
Kwai Han Yoo, Hyewon Lee, Cheolwon Suh
International Journal of Hematology.2018; 107(4): 395. CrossRef
Analysis of prognostic factors in patients with newly diagnosed diffuse large B-cell lymphoma and skeletal involvement
Nicola Lehners, Isabelle Krämer, Maral Saadati, Axel Benner, Anthony D. Ho, Mathias Witzens-Harig
BMC Cancer.2017;[Epub] CrossRef
Outcome prediction by extranodal involvement, IPI, R‐IPI, and NCCN‐IPI in the PET/CT and rituximab era: A Danish–Canadian study of 443 patients with diffuse‐large B‐cell lymphoma
Tarec Christoffer El‐Galaly, Diego Villa, Musa Alzahrani, Jakob Werner Hansen, Laurie H. Sehn, Don Wilson, Peter de Nully Brown, Annika Loft, Victor Iyer, Hans Erik Johnsen, Kerry J. Savage, Joseph M. Connors, Martin Hutchings
American Journal of Hematology.2015; 90(11): 1041. CrossRef
Detailed Analysis of Diffuse Large B Cell Lymphoma Patients: A Single-Center, Retrospective Study
Murat Ozbalak, M. Cem Ar, Nukhet Tuzuner, Ayse Salihoglu, A. Emre Eskazan, Seniz Ongoren Aydin, Zafer Baslar, Teoman Soysal, Yildiz Aydin, Anil Barak Dolgun, Onder Ergonul, Burhan Ferhanoglu
ISRN Hematology.2013; 2013: 1. CrossRef
Prognostic implications of tumor extent in early-stage diffuse large B-cell lymphoma
Changhoon Yoo, Dok Hyun Yoon, Jeong Eun Kim, Jungmin Jo, Seong Joon Park, Shin-Kyo Yoon, Yongchel Ahn, Shin Kim, Jooryung Huh, Dae Ho Lee, Cheolwon Suh
International Journal of Hematology.2013; 97(2): 232. CrossRef
Impact of cutoff age in predicting clinical outcomes of elderly diffuse large B cell lymphoma receiving rituximab or not: A hospital-based study
Ling-Ping Chen, Shyh-Jer Lin, Ming-Sun Yu
Journal of Clinical Gerontology and Geriatrics.2012; 3(1): 36. CrossRef